Artificial intelligence aids in development of nanomedicines for cancer management

P Tan, X Chen, H Zhang, Q Wei, K Luo - Seminars in cancer biology, 2023 - Elsevier
Over the last decade, the nanomedicine has experienced unprecedented development in
diagnosis and management of diseases. A number of nanomedicines have been approved …

Strategies of Artificial intelligence tools in the domain of nanomedicine

H Mohammad, HW You, M Umapathi… - Journal of Drug Delivery …, 2023 - Elsevier
Nanomedicine is a field of medicine that uses nanotechnology to develop new diagnostic
tools and therapies for a wide range of medical conditions. It encompasses a variety of …

Artificial intelligence education: an evidence-based medicine approach for consumers, translators, and developers

FYC Ng, AJ Thirunavukarasu, H Cheng, TF Tan… - Cell Reports …, 2023 - cell.com
Current and future healthcare professionals are generally not trained to cope with the
proliferation of artificial intelligence (AI) technology in healthcare. To design a curriculum …

Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors

JJ Lim, L Hooi, YY Dan, GK Bonney, L Zhou… - Journal of Experimental …, 2022 - Springer
Background Hepatocellular carcinoma (HCC) remains difficult to treat due to limited effective
treatment options. While the proteasome inhibitor bortezomib has shown promising …

Microsystem advances through integration with artificial intelligence

HF Tsai, S Podder, PY Chen - Micromachines, 2023 - mdpi.com
Microfluidics is a rapidly growing discipline that involves studying and manipulating fluids at
reduced length scale and volume, typically on the scale of micro-or nanoliters. Under the …

[HTML][HTML] Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2

K Prasad, V Kumar - Current Research in Pharmacology and Drug …, 2021 - Elsevier
It has been said that COVID-19 is a generational challenge in many ways. But, at the same
time, it becomes a catalyst for collective action, innovation, and discovery. Realizing the full …

The underuse of AI in the health sector: Opportunity costs, success stories, risks and recommendations

U Pagallo, S O'Sullivan, N Nevejans, A Holzinger… - Health and …, 2024 - Springer
Purpose This contribution explores the underuse of artificial intelligence (AI) in the health
sector, what this means for practice, and how much the underuse can cost. Attention is …

Deep learning and drug discovery for healthy aging

P Wang, D Ho - 2023 - ACS Publications
Deep Learning and Drug Discovery for Healthy Aging | ACS Central Science ACS ACS
Publications C&EN CAS Find my institution Log In ACS Central Science ACS Publications. Most …

[HTML][HTML] Addressing antimicrobial resistance with the IDentif. AI platform: Rapidly optimizing clinically actionable combination therapy regimens against …

D Mukherjee, P Wang, L Hooi, V Sandhu, K You… - Theranostics, 2022 - ncbi.nlm.nih.gov
Background: Current standard of care (SOC) regimens against nontuberculous
mycobacteria (NTM) usually result in unsatisfactory therapeutic responses, primarily due to …

IDentif. AI-Omicron: Harnessing an AI-Derived and Disease-Agnostic Platform to Pinpoint Combinatorial Therapies for Clinically Actionable Anti-SARS-CoV-2 …

A Blasiak, ATL Truong, P Wang, L Hooi, DH Chye… - ACS …, 2022 - ACS Publications
Nanomedicine-based and unmodified drug interventions to address COVID-19 have
evolved over the course of the pandemic as more information is gleaned and virus variants …